Abstract
This study reports on a translational exercise in computer-aided rational drug design, chemical synthesis, and bioevaluation using a cell-based reporter gene assay, pursued exclusively for the development of specific estrogen-related receptor γ (ERR γ) inverse agonists with selectivity over estrogen receptor α (ER α). We designed and synthesized a 9-membered small-molecule collection, which has, as the key molecular framework, tetra-aryl-substituted alkene derived from 4-hydroxytamoxifen (4-OHT), a known ERR γ inverse agonist and antagonist of ER α. Although we could not achieve a more potent inverse agonist than GSK5182 from our compound collection, we demonstrated a reasonable correlation between the in silico docking simulation and biological data of transcriptional regulation on nuclear receptors. Therefore, we suggest that structural information regarding proteins-of-interest provides a novel insight into the rational design of new therapeutic agents and that the utilization of docking simulation as a preliminary filtering tool might be a useful option for medicinal chemists or chemical biologists.
Similar content being viewed by others
References
Eudy JD, Yao S, Weston MD, Ma–Edmonds M, Talmadge CB, Cheng JJ, Kimberling WJ, Sumegi J (1998) Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41. Genomics 50: 382–384
Hong H, Yang L, Stallcup MR (1999) Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. J Biol Chem 274: 22618–22626. doi:10.1074/jbc.274.32.22618
Heard DJ, Norby PL, Holloway J, Vissing H (2000) Human ERR γ, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol Endocrinol 14: 382–392. doi:10.1210/me.14.3.382
Alaynick WA, Kondo RP, Xie W, He W, Dufour CR, Downes M, Jonker JW, Giles W, Naviaux RK, Giguere V (2007) ERR γ directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13–24. doi:10.1016/j.cmet.2007.06.007
Ariazi EA, Clark GM, Mertz JE (2002) Estrogen-related receptor α and estrogen-related receptor γ associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62: 6510–6518
Cheung CP, Yu S, Wong KB, Chan LW, Lai FM, Wang X, Suetsugi M, Chen S, Chan FL (2005) Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab 90: 1830–1844. doi:10.1210/jc.2004-1421
Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, Evans RM, Blanchette M, Giguère V (2007) Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERR α and γ. Cell Metab 5: 345–356. doi:10.1016/j.cmet.2007.03.007
Huss JM, Kopp RP, Kelly DP (2002) Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1α) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor- α and - γ. Identification of novel leucinerich interaction motif within PGC-1 alpha. J Biol Chem 277: 40265–40274. doi:10.1074/jbc.M206324200
Yu S, Wang X, Ng C-F, Chen S, Chan FL (2007) ERR γ suppresses cell proliferation and tumor growth of androgensensitive and androgen-insensitive prostate cancer cells and its implications as a therapeutic target for prostate cancer. Cancer Res 67: 4904–4914. doi:10.1158/0008-5472.CAN-06-3855
Horard B, Vanacker J-M (2003) Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endo 31: 349–357. doi:10.1677/jme.0.0310349
Giguère V (2002) To ERR in the estrogen pathway. Trend Endocrinol Metab 13: 220–225. doi:10.1016/S1043-2760(02)00592-1
Chao EYH, Collins JL, Gaillard S, Miller AB, Wang L, Orband-Miller LA, Nolte RT, McDonnell DP, Willson TM, Zuercher WJ (2006) Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRγ. Bioorg Med Chem Lett 16: 821–824. doi:10.1016/j.bmcl.2005.11.030
Kim Y, Koh M, Kim D-K, Choi H-S, Park SB (2009) Efficient discovery of selective small molecule agonists of estrogen-related receptor γ using combinatorial approach. J Comb Chem 11: 928–937. doi:10.1021/cc900081j
Montfort RLM, Workman P (2009) Structure-based design of molecular cancer therapeutics. Trend Biotech 27: 315–328. doi:10.1016/j.tibtech.2009.02.003
Dailey MM, Hait C, Holt PA, Maguire JM, Meier JB, Miller MC, Petraccone L, Trent JO (2009) Structure-based drug design: From nucleic acid to membrane protein targets. Exp Mol Pathol 86: 141–150. doi:10.1016/j.yexmp.2009.01.011
Barker JJ (2006) Antibacterial drug discovery and structure-based design. Drug Discov Today 11: 391–404. doi:10.1016/j.drudis.2006.03.001
Yu DD, Forman BM (2003) Simple and efficient production of (Z)-4-Hydroxytamoxifen, a potent estrogen receptor modulator. J Org Chem 68: 9489–9491. doi:10.1021/jo035164n
Accelrys Software Inc. 10188 Telesis Court, Suite 100 San Diego, CA 92121, USA. http://accelrys.com
Sambrook J, Russel DW (2001) Molecular cloning: a laboratory manual, vol 3, 3rd edn. CSHL Press, New York, pp 16.21–16.26
Greschik H, Flaig R, Renaud J-P, Moras D (2004) Structural basis for the deactivation of the estrogen-related receptor γ by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem 279: 33639–33646. doi:10.1074/jbc.M402195200
Wang L, Zuercher WJ, Consler TG, Lambert MH, Miller AB, Orband–Miller LA, McKee DD, Willson TM, Nolte RT (2006) X-ray crystal structures of the estrogen-related receptor- γ ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J Biol Chem 281: 37773–37781. doi:10.1074/jbc.M608410200
Jordan VC (1995) TAMOXIFEN: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35: 195–211. doi:10.1146/annurev.pa.35.040195.001211
Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44: 112–119
Dugave C, Demange L (2003) Cis–Trans isomerization of organic molecules and biomolecules: implications and applications. Chem Rev 103: 2475–2532. doi:10.1021/cr0104375
Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EJ (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy,4′-hydroxy and N-desmethyl metabolite and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30: 869–874. doi:10.1124/dmd.30.8.869
Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P (2007) Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35: 1942–1948. doi:10.1124/dmd.107.016279
Robertson DW, Katzenellenbogen JA, Logn DJ, Rorke EA, Katzenellenbogen BS (1982) Tamoxifen antiestrogens.A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Ster Biochem 16: 1–13
Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comput Chem 4: 187–217. doi:10.1002/jcc.540040211
Corey EJ, Fuchs PL (1972) A synthetic method for formyl → ethynyl conversion (RCHO → RC≡CH or RC≡CR′). Tetrahedron Lett 13: 3769–3772. doi:10.1016/S0040-4039(01)94157-7
Bauer A, Miller MW, Vice SF, McCombie SW (2001) Suzuki arylation of 1,1-dibromo-1-alkenes: synthesis of tetra-substituted alkenes. Synlett 2: 254–256. doi:10.1055/s-2001-10776
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
The Below is the Electronic Supplementary Material.
Rights and permissions
About this article
Cite this article
Koh, M., Park, S.B. Computer-aided design and synthesis of tetra-aryl-substituted alkenes and their bioevaluation as a selective modulator of estrogen-related receptor γ . Mol Divers 15, 69–81 (2011). https://doi.org/10.1007/s11030-010-9224-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-010-9224-y